Related Experiment Video

Updated: Mar 22, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia

Thomas Perwein1, Sabine Strehl2, Margit König2

  • 1Division of Pediatric Hematology/Oncology, Medical University of Graz, Austria.

Haematologica
|April 30, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
RCSD1-ABL1-positiveacute lymphoblastic leukemiaimatiniblong-term remissionrelapse

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Experiment Videos

Last Updated: Mar 22, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

Articles linked to this work by shared authors, journal, and citation graph.

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Leukemia·2026

Pitfalls and Challenges in the Detection of ZNF384 Rearrangements by Fluorescence in Situ Hybridization.

Genes, chromosomes & cancer·2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Blood·2026

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Pediatric blood & cancer·2026

Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.

Scientific reports·2026

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.

EJHaem·2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Haematologica·2026

Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

Haematologica·2026

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

Haematologica·2026

Normal platelet function in a patient with ARHGEF1 deficiency.

Haematologica·2026

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Haematologica·2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Haematologica·2026

Role of Epigenetic Modifications in The Aberrant Expression of The FOXP3 Gene in Endometriosis: A Case-Control Study.

International journal of fertility & sterility·2026

Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis partly through Interacting with FLI-1.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.

Journal of gastrointestinal oncology·2026

Immune Checkpoint Inhibitor-Induced Diabetes Presenting As Diabetic Ketoacidosis: A Case Report.

Cureus·2026

Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.

Oncoimmunology·2026

A comparison study of thymectomy outcomes in young and older patients with non-thymomatous myasthenia gravis.

Journal of neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us